Selected article for: "dna virus and immune evasion"
Author: Nanbo, Asuka; Furuyama, Wakako; Lin, Zhen
Title: RNA Virus-Encoded miRNAs: Current Insights and Future Challenges
  • Cord-id: bdparerb
  • Document date: 2021_6_24
    • ID: bdparerb
    Snippet: MicroRNAs are small non-coding RNAs that regulate eukaryotic gene expression at the post-transcriptional level and affect a wide range of biological processes. Over the past two decades, numerous virus-encoded miRNAs have been identified. Some of them are crucial for viral replication, whereas others can help immune evasion. Recent sequencing-based bioinformatics methods have helped identify many novel miRNAs, which are encoded by RNA viruses. Unlike the well-characterized DNA virus-encoded miRN
    Document: MicroRNAs are small non-coding RNAs that regulate eukaryotic gene expression at the post-transcriptional level and affect a wide range of biological processes. Over the past two decades, numerous virus-encoded miRNAs have been identified. Some of them are crucial for viral replication, whereas others can help immune evasion. Recent sequencing-based bioinformatics methods have helped identify many novel miRNAs, which are encoded by RNA viruses. Unlike the well-characterized DNA virus-encoded miRNAs, the role of RNA virus-encoded miRNAs remains controversial. In this review, we first describe the current knowledge of miRNAs encoded by various RNA viruses, including newly emerging viruses. Next, we discuss how RNA virus-encoded miRNAs might facilitate viral replication, immunoevasion, and persistence in their hosts. Last, we briefly discuss the challenges in the experimental methodologies and potential applications of miRNAs for diagnosis and therapeutics.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accessory protein and low expression: 1, 2
    • accessory protein and low expression level: 1
    • accessory protein and ltr promoter: 1
    • accessory protein and lung damage: 1
    • acute phase and long term treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute phase and low expression: 1, 2, 3
    • acute phase and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute sars cov respiratory syndrome coronavirus and long term treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute sars cov respiratory syndrome coronavirus and low expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and low expression level: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and ltr promoter: 1
    • acute sars cov respiratory syndrome coronavirus and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lymphoproliferative disorder: 1
    • acute sars cov respiratory syndrome coronavirus and machinery independent: 1
    • acute sars respiratory syndrome coronavirus and ltr promoter: 1, 2
    • acute sars respiratory syndrome coronavirus and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and lymphoproliferative disorder: 1
    • acute sars respiratory syndrome coronavirus and machinery independent: 1